AEMD : Summary for Aethlon Medical, Inc. - Yahoo Finance

U.S. Markets closed

Aethlon Medical, Inc. (AEMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
3.81-0.08 (-2.06%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close3.89
Bid3.70 x 600
Ask4.99 x 200
Day's Range3.81 - 3.91
52 Week Range3.55 - 9.09
Avg. Volume19,912
Market Cap29.43M
PE Ratio (TTM)-4.26
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire9 days ago

    CEO Note - Clinical Study Update and a Review of 2016 Accomplishments

    During the course of 2016, our primary mission was the clinical advancement of our Hemopurifier® in a 10 patient human study being conducted at DaVita Medical Center in Houston. The Hemopurifier® is a first-in-class medical technology currently being advanced in FDA approved studies as a broad-spectrum treatment countermeasure against infectious viral pathogens. The slow pace of the study clouds the fact that 2016 was actually a productive year for our company.  During the year, we completed several study initiatives that reinforce the potential of our Hemopurifier to achieve the broad-spectrum medical countermeasure goal set forth by the U.S. Department of Health and Human Services (HHS) through the Public Health Emergency Medical Countermeasure Enterprise.  In our case, the focus is directed toward virulent viral pathogens that are often not addressed with traditional disease-specific drugs or vaccines.

  • Capital Cube16 days ago

    ETFs with exposure to Aethlon Medical, Inc. : January 3, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Aethlon Medical, Inc. Here are 5 ETFs with the largest exposure to AEMD-US. Comparing the performance and risk of Aethlon Medical, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswirelast month

    Passage of the 21st Century Cures Act and its Potential Implications on Biodefense

    SAN DIEGO, Dec. 21, 2016 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), today released the following note authored by its Chairman and CEO, Jim Joyce. Last week, President Obama signed the 21st Century Cures Act into law.  The $6.3 billion bill establishes new rules that direct the United States Food and Drug Administration (FDA) to approve drugs and devices with greater urgency.  Specific to medical devices, the Act requires the FDA to establish a priority review program for "breakthrough" devices, or for devices that target diseases for which no FDA-cleared or approved alternatives are available.